News
-
-
-
-
COMMUNIQUÉ DE PRESSE
BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator
BRAIN Biotech AG concludes a major pharma compound transaction valued up to EUR 128.88 million, monetizing royalty rights with Royalty Pharma for investigational compound deucrictibant from BioIncubator -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma
BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma -
-
-
COMMUNIQUÉ DE PRESSE
BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year
BRAIN Biotech AG reports strong cash position for 9M period, forecasting growth in Q4 FY 23/24. BioProducts segment turnover slightly up, BioScience segment facing decline -
-
